From the perspective of current and future patients, the development of the field of pharmacogenetics is of immense interest. The encouraging vision that is now being ...

The publication of the human genome sequence has generated great enthusiasm for the potential of gene-based technologies to transform many facets of medical care. Pharmacogenetics — for example, the ...

The genetic polymorphisms that may affect individual responses to cardiovascular agents are reviewed, and the application of pharmacogenetics to cardiovascular disease management is discussed.

Consumer genetics company 23andMe on Wednesday became the first to secure Food and Drug Administration (FDA) approval for a report that provides information about how a person’s genetics may impact ...

Technical hurdles to the wide-spread use of genetic data in humans are disappearing. The cost of sequencing an entire human genome is sinking to around $1,000. Commercial companies are offering ...

Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary The Michigan Oncology Sequencing (MI-Oncoseq) program at The University ...

David Budd, CEO of genedrive plc (Manchester, UK), underscores the emerging role of pharmacogenetics testing in patient safety and treatment efficacy for those with genetic variants modifying their ...

Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes Our findings indicate that approximately one in ...

Alto Partners will exit its minority stake in Diatech Diatech’s founder and management team will retain majority ownership of the company TA Associates is a global private equity firm based in Boston, ...